Naiwanel (Drospirenone, Ethinylestradiol)

• Naiwanel, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent pregnancy and manage menstrual health.
• Prevention of pregnancy: provides reliable contraceptive protection for women of reproductive age.
• Regulation of menstrual cycles: helps achieve more predictable bleeding patterns and reduces cycle irregularities.
• Management of menstrual‑related symptoms: can lessen dysmenorrhea and premenstrual mood changes associated with hormonal fluctuations.

• Drospirenone/Ethinylestradiol works by binding to progesterone and estrogen receptors, suppressing the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH) to inhibit ovulation. It also induces cervical mucus changes that impede sperm penetration and alters the endometrium, making implantation unlikely. These combined actions maintain a hormonal environment that prevents fertilisation and implantation throughout the dosing cycle. The progestogenic component also provides anti‑androgenic effects, contributing to reduced acne and water retention.

Naiwanel may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea: mild stomach upset, especially during the first cycles.
• Breast tenderness: temporary swelling or discomfort of the breasts.
• Headache: mild to moderate head pain that may resolve with continued use.
• Spotting between periods: light vaginal bleeding or spotting.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in deep veins, potentially leading to pulmonary embolism.
• Severe liver disorders: jaundice, hepatic dysfunction, or hepatic adenoma.
• Anaphylaxis: life‑threatening allergic reaction with hives, swelling, or breathing difficulty.

Before prescribing Naiwanel, clinicians should evaluate patient risk factors and provide appropriate counseling.

• Assess cardiovascular risk: review history of thrombosis, hypertension, or smoking.
• Avoid smoking: especially in women over 35 years of age due to increased clot risk.
• Monitor blood pressure: check regularly during treatment.
• Review concomitant medications: consider potential drug interactions that may affect efficacy.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Naiwanel can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce contraceptive efficacy.
• Additional estrogen‑containing products (e.g., hormone replacement therapy): increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely)

• Antifungal azoles (e.g., ketoconazole): can increase hormone plasma levels, potentially enhancing side effects.
• Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency.
• St. John’s wort: may lower hormone concentrations, reducing contraceptive reliability.